Drugs / Depo-subQ Provera
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04682353 Comparator | Dec 2020 → Jul 2022 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Depo-subQ Provera | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04682353 ↗ |
| Route | Subcutaneous | “SC injection of 104 mg/0.65 mL” NCT04682353 ↗ |